BioCatalystWatch
MRNAWorkspace / MRNA / OverviewCompany library
Price
Market cap
Next catalystDec 12, 2026mRNA-2808 — relapsed/refractory multiple myeloma · Phase 1/2 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

mRNA-2808

BCMA × GPRC5D × FcRH5 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
Upcoming / outlook

intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
Upcoming / outlook

mRNA-1769

Four mpox antigens

PreINDP1P2P3FilingApproved
Upcoming / outlook

mRNA-1195

Lytic EBV antigens × Latent EBV antigens × EBNA3A × LMP2B × EBV gH

PreINDP1P2P3FilingApproved
mRNA-4359

PD-L1 × IDO1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
Upcoming / outlook

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
Upcoming / outlook

mRNA-4359

PD-L1 × IDO1

PreINDP1P2P3FilingApproved
Upcoming / outlook

mRNA-1769

Four mpox antigens

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved

intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved
intismeran autogene

Patient-specific tumor neoantigens

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Partner / License out

Approved / commercial

Prefusion RSV F

PreINDP1P2P3FilingApproved

Influenza hemagglutinin (HA)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

History / paused

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
mRNA-1647

CMV pentamer complex × CMV gB

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MRNA SEC archive